Siao-Yi Wang, MD
Medical Oncology · Sacramento, CANPI 1134540859
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,624 of the $4,601 with a category attached, or 78.8%. Regeneron accounts for 78.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $4,138 and has fallen 96.1% since, to $161 in 2024. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 18 payments — averaging $255.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$4K
- Foundation Medicine, Inc.$229
- Tempus AI, Inc$161
- Exelixis Inc.$157
- Merck$140
- E.r. Squibb & Sons, L.L.C.$99
- plus $192 from 8 others
Across 4 payments — averaging $24,564 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$98K
What the payments were for
- Consulting fees$3,62479%
- Food & beverage$97721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 2 | $3,624 |
| Foundation Medicine, Inc. | 1 | $229 |
| Tempus AI, Inc | 1 | $161 |
| Exelixis Inc. | 1 | $157 |
| Merck | 2 | $140 |
| E.r. Squibb & Sons, L.L.C. | 1 | $99 |
| Johnson & Johnson | 1 | $39 |
| AstraZeneca | 2 | $34 |
| Sanofi | 2 | $33 |
| Amgen | 1 | $24 |
| Novartis | 1 | $18 |
| CTI Biopharma Corp. | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$3,624
- FOUNDATIONONE CDX$229
- XT CDX$161
- Cabometyx$157
- KEYTRUDA$123
How this compares
$4,601 in reported general payments places this provider in the 50th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 13 | $308,897 |
| Tirosint-SolLevothyroxine Sodium | 13 | $1,812 |
| SynthroidLevothyroxine Sodium | 16 | $1,238 |
| Prochlorperazine Maleate | 37 | $448 |
| Ondansetron Hcl | 24 | $194 |
| Dexamethasone | 54 | $191 |
| Lidocaine Hcl ViscousLidocaine Hcl | 15 | $183 |
| LoperamideLoperamide Hcl | 13 | $170 |
| Olanzapine | 34 | $23 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Sacramento
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.